Exposure-response modeling improves selection of radiation and radiosensitizer combinations by Cardilin, Tim et al.
Exposure-response modeling improves selection of radiation and
radiosensitizer combinations
Downloaded from: https://research.chalmers.se, 2022-01-01 18:18 UTC
Citation for the original published paper (version of record):
Cardilin, T., Almquist, J., Jirstrand, M. et al (2021)
Exposure-response modeling improves selection of radiation and radiosensitizer combinations
Journal of Pharmacokinetics and Pharmacodynamics, In Press
http://dx.doi.org/10.1007/s10928-021-09784-7
N.B. When citing this work, cite the original published paper.
research.chalmers.se offers the possibility of retrieving research publications produced at Chalmers University of Technology.
It covers all kind of research output: articles, dissertations, conference papers, reports etc. since 2004.
research.chalmers.se is administrated and maintained by Chalmers Library
(article starts on next page)
ORIGINAL PAPER
Exposure-response modeling improves selection of radiation
and radiosensitizer combinations
Tim Cardilin1,2 • Joachim Almquist1,6 • Mats Jirstrand1 • Astrid Zimmermann3 • Floriane Lignet4 •
Samer El Bawab4 • Johan Gabrielsson5
Received: 30 March 2021 / Accepted: 19 September 2021
 The Author(s) 2021
Abstract
A central question in drug discovery is how to select drug candidates from a large number of available compounds. This
analysis presents a model-based approach for comparing and ranking combinations of radiation and radiosensitizers. The
approach is quantitative and based on the previously-derived Tumor Static Exposure (TSE) concept. Combinations of
radiation and radiosensitizers are evaluated based on their ability to induce tumor regression relative to toxicity and other
potential costs. The approach is presented in the form of a case study where the objective is to find the most promising
candidate out of three radiosensitizing agents. Data from a xenograft study is described using a nonlinear mixed-effects
modeling approach and a previously-published tumor model for radiation and radiosensitizing agents. First, the most
promising candidate is chosen under the assumption that all compounds are equally toxic. The impact of toxicity in
compound selection is then illustrated by assuming that one compound is more toxic than the others, leading to a different
choice of candidate.
Keywords Radiosensitizer  Tumor Static Exposure  Treatment optimization  Tumor growth model  Drug selection
Introduction
Radiotherapy is a cornerstone of modern oncology, and is
frequently given in conjunction with chemical treatments
to improve efficacy [1, 2]. Radiosensitizers are a class of
chemical agents designed to enhance the radiation effect,
e.g. by interfering with the cell’s repair of radiation-
induced DNA damage [3]. During preclinical development
of novel compounds, including radiosensitizers, a central
question is how to select the most promising compounds
from a large number of candidates [4–6]. Proper assess-
ment of radiation and radiosensitizer combinations requires
studies of efficacy as well as toxicology and adverse effects
[7]. All compounds and doses cannot be tested in vivo—for
reasons of time, resources, and ethics [8]. Experimental
studies must therefore be supported by cheaper alternatives
such as computer modeling and simulations [9, 10].
Numerous quantitative models have been developed to
describe the effects of radiotherapy on tumors, with or
without chemical intervention [11–14]. These models
range from the simple, yet ubiquitous, linear-quadratic
model of radiobiology [15], to complex systems pharma-
cology models that include particular pathways and pro-
cesses (such as the cell cycle) that are relevant to the given
treatment [16, 17]. In radiation oncology, models of Tumor
Control Probability (TCP)—defined by whether a given
radiation dose controls or eradicates an irradiated tumor—
are commonly employed alongside Normal Tissue Com-
plication Probability (NTCP) models that quantify toxi-
cology and adverse risks [18–20].
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Models have also been developed to describe the effects
of radiotherapy on tumor volume over time. Watanabe
et al. [21] proposed a radiation model with gradual cell
death in response to single-dose treatment, and used it to
describe tumor growth over time in rat rhabdomyosarcoma
and in patients with metastatic brain tumors. More recently,
Husband et al. developed and evaluated radiation models
that describe tumor growth and survival in patient-derived
xenograft mice for diffuse intrinsic pontine glioma [22].
In two earlier papers, we developed models that describe
tumor growth in xenograft mice receiving radiotherapy and
neoadjuvant radiosensitizing treatment [23, 24]. We also
introduced the Tumor Static Exposure (TSE) concept—a
model-based prediction of all combinations of radiation
doses and radiosensitizer concentrations that result in
tumor regression. However, these models only consider a
single radiosensitzing compound and can therefore not
fully illustrate the utility of the TSE concept in aiding the
drug selection process.
In this paper, we use TSE to compare and rank three
different combinations of radiation and radiosensitizing
agents. One of our earlier models is used with data from a
xenograft study involving radiotherapy administered alone
or together with either of the radiosensitizers. The com-
pounds are ranked by weighing efficacy (measured using
TSE) against toxicity. Two different toxicological models
are considered: a simple, linear model; and a more complex
NTCP model adjusted to account for radiosensitizing
treatment [25]. We also introduce the concept of Tumor
Shrinkage Exposures, which can be used if tumor stasis is
insufficient and tumor shrinkage with a particular rate is
desired.
Methods
Experimental data are first described. Then, a previously-
developed tumor model used to describe radiation and
radiosensitizer combination therapies is summarized.
Thereafter, a method for comparing and ranking radiation
and radiosensitizer combinations, based on TSE, is pre-
sented. The method optimizes a given cost function, used
to describe, e.g., toxicity and other adverse effects, along
the TSE curve. Finally, computational aspects of the non-
linear mixed-effects modeling approach are provided.
Experimental data
Pharmacodynamic data were generated in FaDu xenograft
mouse models treated with radiation either alone or toge-
ther with one of three early-discovery radiosensitizing
compounds, henceforth referred to as compounds A1, A2,
and A3. A total of 54 female mice were divided into six
treatment groups with nine mice in each group: (A) vehicle
control, (B) monotherapy with radiation (2 Gy per dose),
(C) combination therapy with radiation (2 Gy per dose)
and compound A1 (100 mg/kg per dose), (D) combination
therapy with radiation (2 Gy per dose) and compound A2
(25 mg/kg per dose), (E) combination therapy with radia-
tion (2 Gy per dose) and compound A2 (100 mg/kg per
dose), and (F) combination therapy with radiation (2 Gy
per dose) and compound A3 (20 mg/kg per dose). Doses
were given once per day Mon–Fri for 6 weeks.
Exposure data were generated in FaDu xenograft models
for the compounds A1, A2, and A3. Single doses of the
compounds A1, A2, and A3 were given orally to 16 animals
divided into four treatment groups with four mice in each
group: compound A1 (100 mg/kg), compound A2 (25 mg/
kg), compound A2 (100 mg/kg) and compound A3 (20 mg/
kg) Drug concentration in plasma was measured after 1, 2,
and 6 h.
Experiments were approved in accordance with German
animal welfare regulations by the Regierungspräsidium
Darmstadt, Hessen, Germany (protocol registration num-
bers DA 4/Anz. 397 and DA 4/Anz. 398).
Tumor model for radiation and radiosensitizer
combination treatment
We use a previously-developed radiation model (Fig. 1) to
describe tumor growth following treatment with radiation
and radiosensitizing agents [23]. The model consists of a
main compartment V1 representing proliferating cancer
cells, three damage compartments V2, V3, and V4, that all
Fig. 1 Tumor model used to describe combination therapy with ion-
izing radiation (IR) and radiosensitizer compounds. Cancer cells in
compartment V1 proliferate with rate kg and are eliminated with rate
kk. Dying cells are transferred through three damage compartments
V2, V3 and V4. Lethally irradiated cells are moved to a radiation-
damage compartment U1 where they are allowed up to one more cell
division, before dying. The compartment U2 represents irradiated
cells after one cell division that can no longer divide
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dying cells traverse, and two radiation compartments U1,
and U2, that allow irradiated cells up to one more cell
division before dying. Irradiated cells are instantaneously
transferred from V1 to U1. The fraction of proliferating
cells that is transferred is based on the well-established
linear-quadratic formula from radiobiology [14, 15].
Moreover, the presence of a radiosensitizing agent is
accounted for via an increase in the number of lethally
irradiated cells depending on the plasma concentration of
the radiosensitizer at the time of irradiation. A high plasma
concentration leads to a greater transfer of cells from V1 to
U1. The model also incorporates natural cell death, mean-
ing that some cells traverse the damage compartments even
for untreated tumors.




¼ kgV1  kkV1
dV2
dt
¼ kkV1 þ kkU1 þ kkU2  kkV2
dV3
dt
¼ kkV2  kkV3
dV4
dt
¼ kkV3  kkV4
dU1
dt
¼ kgU1  kkU1
dU2
dt
¼ 2kgU1  kkU2
ð1Þ
where kg is the growth rate of proliferating cancer cells,
and kk the kill rate of cancer cells which is assumed to be
the same for all compartments. The use of growth rate kg
and the presence of the factor two in the transfer from U1 to
U2 describes that cell division occurs between these states
and therefore twice as many cells enter U2 than leave U1.
Radiation treatment is implemented as sudden transfer
between compartments V1 and U1, corresponding to an
instantaneous transfer of cells with the fraction given by (1-
SF (DIR,Ci)). Here, SF (DIR,Cj) is the surviving fraction of
proliferating cancer cells given a radiation dose DIR and
concurrent drug plasma concentration Cj of compound Aj.
Mathematically this can be described by the two equations
V1 t
þ
ið Þ ¼ V1 ti
 









ið Þ ¼ U1 ti
 













be interpreted as times just before and after irradiation.
Note that radiation dose is given in terms of Gray (Gy),
which is absorbed dose measured in joules per kilogram,
i.e., the radiation dose is normalized with respect to animal
weight and hence plays the role of exposure to radiation.
The surviving fraction is given by
SF DIR;Cj
 





where a and b are the linear and quadratic coefficients
associated with radiation DNA damage, and aj is the
pharmacodynamic parameter associated with the
radiosensitizing capabilities of compound Aj. The initial
conditions for the system are given by




; Ui 0ð Þ ¼ 0; ð4Þ
where V0 is the initial volume of the main compartment.
With these initial conditions, untreated tumors grow
exponentially with net growth rate kg - kk [26]. The total
tumor volume, Vtotal, is obtained as the sum of all
compartments
Vtotal ¼ V1 þ V2 þ V3 þ V4 þ U1 þ U2 ð5Þ
Comparing combinations of radiation
and radiosensitizers
In the case study, the goal is to select one of three
radiosensitizing agents for further experimental study. We
propose a model-based approach that evaluates combina-
tions based on how easily tumor regression is achieved,
relative to toxicological or other adverse effects. The
model described in the previous section is calibrated to data
and then used to derive TSE curves for each radiosensi-
tizing agent. Cost functions are introduced to describe
toxicology and other potential costs associated with treat-
ment, and an optimization problem is formulated to mini-
mize the cost subject to the constraint that the tumor does
not grow, i.e., that the exposure is on or above the TSE
curve.
The Tumor Static Concentration (TSC) and TSE con-
cepts have been introduced and used in several earlier
papers [26–29]. The TSC curve corresponding to a par-
ticular combination therapy consists of all pairs (C1, C2) of
plasma concentrations for which a maintained exposure
leads to tumor stasis. In particular, maintaining exposure
levels above the TSC curve leads to tumor regression. The
TSE concept is a generalization of TSC that allows for
treatments for which concentrations are unknown or not
applicable, such as radiotherapy. The TSE curve for the
model given in Eqs. 1 and 2 has previously been derived
(see [23]). The curve consists of combinations of daily
radiation doses and average radiosensitizer concentrations
such that the tumor is kept in approximate stasis.
In the Results section, the calibrated tumor model is
used to generate TSE curves for combination therapy with
radiation and each of three radiosensitizers, which we
denote A1, A2, and A3. We propose the following
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procedure for comparing and ranking combinations, while
accounting for toxicity and other adverse effects.
For each treatment combination, introduce an associated
cost function W (E1, E2), where E1 and E2 refer to general
exposure metrics. In our case study E1 = DIR is radiation
dose, and E2 = Cj is the concurrent plasma concentration of
radiosensitizer Ai. Alternatively, nondimensional expo-
sures could be defined by E1 = DIR/Dref and E2 = Cj/Cref,j,
where Dref and Cref,j are reference exposures. The cost
function is a way to measure the toxicity of the combina-
tion, although other kinds of costs could also be included.
W is an increasing function, reflecting that a larger value
corresponds to higher cost/toxicity.
In the simplest case, W is linear function and is given by
W E1;E2ð Þ ¼ pE1 þ qE2; ð6Þ
where p/q is the relative toxicity of the two compounds,
assumed to be constant. Equation 6 assumes that toxicity
increases linearly with exposure and is additive. Exposure
pairs of equal costs, i.e., the level curves W (E1, E2-
) = constant, are in this case lines with slope - p/q, with
E1 and E2 are on the horizontal and vertical axes, respec-
tively. An example of a TSE curve and a level set of the
cost function is shown in Fig. 2.
As an example of a more intricate cost function, we
utilize the established framework around NTCP [18, 19].
Such models are commonly used to describe the proba-
bility of adverse events following radiation treatment
[30–32]. A widely used model for NTCP is the Lyman–
Kutcher–Burman (LKB) model which defines the NTCP as







where the variable t is defined by
t ¼ Deff  TD50
mTD50
; ð8Þ
and where Deff is the effective dose, which accounts for
non-uniform dose distribution, TD50 is the dose associated
with 50% complication risk, and m is a slope parameter for
the sigmoidal curve [25, 33]. From these equations we can
see that a larger value of Deff corresponds to a larger value
for t, which in turns means a greater risk of complications.
The key question when defining a cost function for
radiation and radiosensitizer combinations is how to
introduce radiosensitizing treatment into the NTCP model.
Since TD50 is a typical measure of radiation sensitivity, we
propose to let the radiosensitizer modulate this parameter
and thereby increase the risk of complications. Assuming
an exponential sigmoidal modulation function gives a new
definition of t,
t ¼ Deff  TD50I Cð Þ
mTD50I Cð Þ
ð9Þ
where I(C) is an exponential inhibitory function with
parameter ks [34]:
I Cð Þ ¼ exp ksCð Þ: ð10Þ
We can thus use the NTCP model as a cost function with
exposures E1 = Deff = D (total radiation dose) and E2 = C,
where C is the radiosensitizer concentration at the time of
irradiation. Note that NTCP depends on the exposures E1
and E2 only through the variable t. Therefore, exposure
combinations with equal complication risk have the same
value for t. Thus, solving for Deff in Eq. 9 gives the
expression for equal cost
Deff ¼ 1þ mtð ÞTD50 exp ksCð Þ: ð11Þ
Equation 10 describes a sigmoidal relationship between
exposure pairs (Deff, C) with equal cost.
Equipped with a cost function, we search along the TSE
curve for the exposure pair with the lowest cost. Repeating
this procedure for each combination gives a sequence of
lowest costs, each corresponding to a different combination
therapy. These values can then be used to compare and
rank combination therapies.
The procedure for comparing and ranking combinations
is summarized below:
(1) Choose a suitable tumor model given available data
and calibrate the model to obtain parameter estimates
(2) Compute the TSE curves and insert the estimated
parameter values
Fig. 2 TSE curve for two compounds with exposures E1 and E2
(blue). Exposure pairs above the curve give rise to tumor shrinkage,
whereas exposure pairs below the curve result in tumor growth. A
level set where the cost W is constant is shown in black, dashed, with
the corresponding W* (color figure online)
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(3) Choose an appropriate cost function W for each
combination and find the minimum cost W* along the
TSE curve
(4) Repeat Steps 1–3 for each drug combination
(5) Compare W* across combination therapies and
choose the combination with the lowest cost
Tumor shrinkage exposures
TSE curves are based on the requirement of tumor stasis.
This is valuable since the curve divides the exposure plane
into regions of tumor growth and tumor shrinkage. How-
ever, in practice, tumor shrinkage may not be enough and
one can therefore look at tumor shrinkage with different
rates. This leads to a generalization of TSE called tumor
shrinkage exposure (TSEq) where q is the relative change
in volume for a given time unit, q ¼ V t1ð ÞV t2ð ÞV t1ð Þ , where
t2[ t1 are two time point, and t2 - t1 is the chosen time
unit. In particular, TSE0 is the regular TSE curve, and
TSE0.5 requires that the tumor shrinks by 50% of its size
every for every unit of time that elapses. TSEq is derived
analogously to TSE, with the difference that the growth
rate is set to a constant different from zero. The concept of
TSEq curves is illustrated for the case study in the Results
section.
Computational methods
The tumor model was calibrated to xenograft data using a
nonlinear mixed-effects approach based on the first-order
conditional estimation (FOCE) method in a computational
framework developed at the Fraunhofer-Chalmers
Research Centre for Industrial Mathematics (Gothenburg,
Sweden) and implemented in Mathematica (Wolfram
Research) [35]. Exposure data for compounds A1, A2, and
A3 were described using one-compartment pharmacoki-
netic models. Model evaluation was based on goodness-of-
fit, empirical Bayes estimates, and residual analysis.
Lognormal distributed between-subject variability was
added to the initial volume of the main compartment V0
and the growth rate kg. Residual errors were assumed to be
proportional to tumor volume with zero mean and variance
r2V . As done previously, the ratio between a and b was set
to 10 [23, 36].
Results
First, the results of fitting the tumor model to the experi-
mental data are presented. Then, TSE curves corresponding
to combination therapy with radiation and each of the three
radiosensitizers A1, A2, and A3, are computed. Finally, the
procedure for comparing and ranking combinations is
illustrated for two toxicological settings.
Tumor model for radiation and radiosensitizer
combination treatment
Exposure profiles for each of the three radiosensitizers A1,
A2, and A3 were described by standard one-compartment
pharmacokinetic models, with parameter estimates given in
Table 1. Simulated PK profiles used to drive the pharma-
codynamic tumor model are shown in Fig. 3. The exposure
of compound A1 (green) was approximately ten times
lower than the exposures of compounds A2 (blue) and A3
(purple).
The tumor model adequately described observed data
from each of the six treatment groups. Examples of indi-
vidual fits for each treatment group are shown in Fig. 4. In
the vehicle group, tumor growth was approximately
exponential during the observed time period. Tumors
treated with radiation monotherapy reached approximate
stasis during treatment and in some cases showed signs of
regression. Tumors treated with radiation and compound
A1 combination therapy exhibited significant regression
and in most cases the tumors were eradicated. Tumors
treated with radiation and compound A2 showed significant
regression with the lower dose (25 mg/kg) and in most
cases tumor eradication with the higher dose (100 mg/kg).
Lastly, tumors treated with radiation and compound A3
also exhibited tumor eradication in most instances. Visual
predictive checks for the tumor model can be found in
Supplemental Information S1.
The parameter estimates from fitting the tumor model
simultaneously to all treatment groups are given in Table 2.
The net growth rate kg  kk ¼ 0:16=day corresponds to an
average doubling time of 4.3 days for the vehicle group.
System and radiation parameters were estimated with good
precision, whereas drug parameters were estimated with
lower but still acceptable precision (RSE\ 40%).
TSE curves for radiation and radiosensitizer
combinations
Following the same principles as in [23] the following







 2þ4 bþ ajbCj
 





where DIR is the radiation dose given every T days, and Cj
is the plasma concentration of Aj at the instance of irra-
diation. The details can be found in Supplemental Infor-
mation S2.
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The TSE curves for the three combination therapies
involving radiation and one of the radiosensitizing agents
A1, A2, and A3, were computed by inserting the parameter
estimates from Table 2 into Eq. 12, using T = 1 day to
indicate daily dosing. The resulting TSE curves are shown
in Fig. 5.
Fig. 3 Simulated PK profiles for compounds A1, A2, and A3 with corresponding plasma concentrations C1, C2, and C3. Doses of 100 mg/kg
(compounds A1 and A2) or 20 mg/kg (compound A3) were given 5 days a week for 6 weeks
Fig. 4 Examples of individual
fits for each of the six treatment
groups: vehicle (black),
radiation monotherapy with
2 Gy per dose (red),
combination therapy with
radiation and A1 at 100 mg/kg
per dose (green), combination
therapy with radiation and A2 at
25 mg/kg or 100 mg/kg per
dose (blue), and combination
therapy with radiation and A3 at
20 mg/kg per dose (purple)
(color figure online)
Table 1 Parameter estimates for
the one-compartment
pharmacokinetic models
describing exposure to the
compounds A1, A2, and A3 in
terms of plasma concentration
Parameter Compound Population median (RSE%) Between-subject variabilitya (RSE%)
ke (/h) A1 0.092 (9) 63 (15)
A2 0.35 (7) 18(13)
A3 0.27 (9) 6 (13)
V (L/kg) A1 110 (8) 26 (14)
A2 12 (8) 14 (17)
A3 2.6 (6) 2 (21)
rbc(%) A1 14 (25) –
A2 15 (22) –
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The TSE value for radiation monotherapy was estimated
to 1.3 Gy, meaning that for the median individual a daily
dose of 1.3 Gy would be sufficient for approximate tumor
stasis. Since the compounds A1, A2, and A3, have no
monotherapy effect, they have no TSE values. Instead, the
TSE curves asymptotically approach the concentration axis
as the plasma concentrations of the compounds approach
infinity. The TSE curve for combinations of radiation and
compound A1 (left) exhibits the largest curvature. Indeed,
that TSE curve associated with A1 lies strictly below the
TSE curve for the other two combination therapies.
Comparing combinations of radiation
and radiosensitizers
The procedure outlined in the Methods section is applied to
compare and rank the three combination therapies for two
toxicological models. Using the first model, we consider
two scenarios: one based on the assumption that all
radiosensitizers are equally toxic, and one where the toxi-
city of compound A1 is increased tenfold. The cost func-
tions are given by
W DIR;Cj
 
¼ pDIR þ qjCj ð13Þ
where DIR is the radiation dose with toxicity coefficient p,
and Cj is the plasma concentrations of compound Aj with
toxicity coefficient qj. First, assuming that all test com-
pounds are equally toxic means that q1 = q2 = q3. The
costs associated with each combination pair (DIR, Cj) on
the corresponding TSE curve are illustrated in Fig. 6 (left).
The parameter s indicates the location along the TSE curve
with s = 0 corresponding to radiation monotherapy, and
s = 1 corresponding to monotherapy with the radiosensi-
tizer. Note that, for the particular tumor model in this case
study, the radiosensitizers have no monotherapy effect,
which means that s = 1 corresponds to an infinitely large
exposure of the radiosensitizer and therefore also an infi-
nite cost/toxicity. The parametrization has been performed
Fig. 5 TSE curves for combinations of radiation and radiosensitizers
A1 (left), A2 (middle) and A3 (right) obtained by inserting the
parameter estimates from Table 2 into Eq. 12. TSE curves are shown
in blue. Regions above and below the curves correspond to
combination pairs that result in tumor shrinkage, or tumor growth,
respectively. The dashed reference lines indicate the daily radiation
dose required for tumor shrinkage during monotherapy
Table 2 Parameter estimates for the tumor model describing the effects of radiation and radiosensitizer combination therapy
Parameter Population median (RSE%) Between-subject variabilitya (RSE%) Description
kg (/day) 0.50 (5) 53 (2) Natural growth rate
kk (/day) 0.34 (5) – Natural kill rate
V0 (mm3) 26.0 (8) 7 (11) Initial volume of main compartment
a (/Gy) 0.11 (6) – Linear radiation parameter
b (/Gy2) 0.011 (6) – Quadratic radiation parameter
a1 (mL/lg) 0.27 (33) – Pharmacodynamic parameter of A1
a2 (mL/lg) 0.038 (36) – Pharmacodynamic parameter of A2
a3 (mL/lg) 0.028 (35) Pharmacodynamic parameter of A3
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such that s = 0.5 corresponds to Cj = 25 lg/mL. This is an
arbitrary scaling of the parametrization that does not affect
the optimization problem and is performed only to make
the figures easier to interpret. This amounts to the
parametrization given in Eq. 14 below







with DIR (Cj) given as in Eq. 12.
The cost coefficients were set to p = 100/Gy and qj-
= 1 mL/lg. Figure 6 (left) shows that combination ther-
apy with A1 has the lowest cost (for s & 0.5Þ. We then
consider the second scenario, where the toxicity of A1 has
been increased by a factor ten, q1 = 10 mL/lg, which is
illustrated in Fig. 6 (right). A1 is no longer the best treat-
ment option, since A2 and A3 both have lowers costs (oc-
curring at s & 0.6).
Figure 7 shows the results using the more complex
NTCP model as cost function. For this model, we use
values of TD50 = 50 Gy and m = 0.5 to describe radiation
treatment and set the radiation parameter ks to 0.02 mL/
lg/day for all three radiosensitizers. Similar to the case
with a linear cost function, A1, which is the most effica-
cious, has the lowest cost. Compared with the linear case,
the value of the radiosensitizer parameter ks for A1 would
need to be decreased approximately tenfold for another
radiosensitizer to become the most promising candidate.
The parametrization of the cost function along the TSE
curve, with parameter s going from s = 0 (radiotherapy) to
s = 1 (radiosensitizer monotherapy) is given in Eq. 15.













where DIR is given by Eq. 12, I is given by Eq. 10, and
NTCP is given by Eq. 9.
Fig. 6 Hypothetical costs W for different combinations along the TSE
curves in Fig. 5 for combination therapy with radiation and
radiosensitizers A1 (green), A2 (blue), and A3 (purple). The left plot
assumes that all three compounds are equally toxic, whereas in the
right plot the toxicity of A1 (green) has been increased by a factor ten.
The parameter s represents the position on the TSE curve with s = 0
corresponding to radiation monotherapy and s = 1 monotherapy with
compound Aj (color figure online)
Fig. 7 Hypothetical costs W
using the NTCP model (Eq. 15)
for radiation and radiosensitizer
combinations, A1 (green), A2
(blue), and A3 (purple), along
the TSE curves in Fig. 5. The
left plot assumes equal toxicity,
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Tumor shrinkage exposures
Figures 5 and 6 are used to minimize the cost of combi-
nation therapy with the respect to the TSE curve, i.e., while
making sure the tumor is not growing. As pointed out in the
Methods section, it is also possible to require that the
tumors shrink at a specified rate, by introducing the TSEq
curves. TSEq curves are illustrated in Fig. 8 for combina-
tions of radiation and compound A2, assuming a linear cost
function as in Fig. 6. The three TSEq curves (blue) consists
of exposure pairs (DIR, Cj) that keep the tumor in stasis,
shrink the tumor to half its size, and shrink the tumor to one
eighth of its size, respectively.
For each TSEq curve, it is possible to minimize the costs
of combination therapy following the same procedure as
described earlier. Thus, for a given combination, consider
how the minimum cost, Wmin, varies depending on how
quickly the tumor is required to shrink, i.e., q. Figure 9
depicts this scenario for combinations of radiation and the
three radiosensitizers as a function of the parameter
1=1 q under the assumption that all compounds are
equally toxic. Note that combination therapy with A1
(green) always has the lowest cost.
Discussion
Recent decades have seen a growing focus on combination
therapies as a way to combat resistances and to obtain
synergistic effects [37, 38]. Our analysis of radiotherapy
and radiosensitizer combinations in this paper is focused on
the latter, while also addressing toxicity and side-effects.
As with any model-based analysis, good predictions and
results are contingent not only on data [39], but also on
sound modeling methodology [40, 41]. Details on this
topic, particularly in the context of oncology, can be found
e.g. in several papers by Mould et al. [42–44]. The
remainder of this discussion considers, in order: the
mathematical tumor model, the resulting TSE curves and
concepts, and, finally, our proposed optimization and
ranking procedure for radiation and radiosensitizer
combinations.
Tumor model for radiation and radiosensitizer
combinations
The model used in this paper in based on an earlier model
(see [23]), with two minor differences. As in [24] an
exponential growth function was favored over logistic
growth, since it proved sufficient to describe vehicle data
and no plateaus in tumor volumes were observed. Sec-
ondly, we assumed no monotherapy effect for the
radiosensitizers, which is expected to be negligible given
that the compounds interact with the repair mechanisms of
DNA damage induced by irradiation.
The growth and kill rates were estimated to similar
values to those in [23, 24], and the net growth rate kg - kk
of 0.15/day, corresponds to a doubling time of 4–5 days,
which is similar to other models [21, 23, 26, 27, 45]. The
estimated a and b values of 0.11/Gy and 0.0011/Gy2 are in
line with reported ranges of 0.02 - 0.2 for a and
0.001 - 0.6 for b [46]. Model parameters were estimated
Fig. 8 Examples of TSE curves for combinations of radiation and
compound A2. TSE1, TSE2, and TSE8 corresponding to shrinkage
rates that keep the tumor in stasis, reduce the tumor to half its size,
and reduce the number of proliferating tumor cells to one eighth of its
size with each daily dose, respectively
Fig. 9 Minimal costs w* as a function of relative shrinkage rate q for
combinations of radiation and A1 (green), A2 (blue), and A3 (purple).
Here
1
1 q ¼ V1 t1ð Þ=V1 t2ð Þ
is a more natural parameter such that the minimal cost is an
increasing function of the parameter. The figure shows that, for any
value of q, the compound A1 has the lowest cost, since the curves
never intersect
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with reasonable precision, although the radiosensitizer
parameters ai had somewhat lower precision
(RSE% & 35), which is partially explained by the fact that
each ai is only informed by one or two treatment groups,
whereas other model parameters are informed by all data.
Like many tumor models used preclinically, our model
contains a sequence of damage compartments
[26, 27, 29, 45], and can be viewed as a combination of
these models with the linear-quadratic model in radiobi-
ology [15], or compartment radiation models that imple-
ment the linear-quadratic model with delay [21, 22].
Compared with systems pharmacology models for radia-
tion and chemical combinations, e.g., Checkley et al. [17],
Kosinsky et al. [16], our model is simpler and, although
less mechanistic, can be calibrated to standard xenograft
data.
TSE curves for radiation
and radiosensitizer combinations
TSC and TSE have been developed and applied in a series
of papers [23, 26, 27, 29]. They are tailored specifically to
cancer treatments (single-agents or combinations), and are
connected to qualitative behavior (tumor growth or
shrinkage) of the disease as well as synergy, unlike general
models such as the isobologram [47, 48] and the half-
maximal effect curve [49] which focus only on synergy. In
radiation oncology, TCP models are used to assess proba-
bilities of tumor eradication, recurrence, or emergence of
metastases [20, 50], which is similar to TSE in that it also
aims to control or destroy cancer cells.
In our analysis, greatest synergy occurred with
radiosensitizer A1, which can also be seen from the cur-
vatures of the TSE curves (Fig. 5). This happens because
although observed tumor growth was similar across com-
binations, exposure levels were approximately ten times
lower for compounds A1 (see Fig. 3). However, proper
assessment requires consideration not only of efficacy, but
joint consideration of efficacy and toxicity.
Comparing combinations of radiation
and radiosensitizers
In our case study involving radiation and three radiosen-
sitizing agents, Fig. 6 (left) shows that radiosensitizer A1 is
the superior radiosensitizer given that all compounds are
equally toxic, which holds for either cost function. More-
over, Fig. 6 (right) shows that the toxicity of A1 would
have to be increased tenfold over A2 and A3 for another
radiosensitizer to become preferable. This result held true
for both cost functions. However, since the NTCP model is
nonlinear and contains multiple sigmoidal functions, these
results depend on the chosen parameter values.
Our proposed method evaluates combinations of radia-
tion and radiosensitizers by the ability to induce tumor
regression relative to toxicity. Two toxicity functions, or
cost functions are considered: one linear, and one based on
NTCP. The former approach was also considered in [29] to
find an optimal combination for two anticancer com-
pounds. A similar analysis can be found in [51] where
phase one clinical data were used to construct a toxicity
function with linear terms as well as a quadratic term to
penalize combination treatment.
In radiotherapy, TCP and NTCP models are often
combined to optimize treatment [52, 53]. In our analysis,
the tumor model together with TSE appear instead of a
TCP model, which we consider in conjunction with the
commonly used Lyman NTCP model [25]. Here, we note
similar results using a linear model and an NTCP model
(see Figs. 6, 7) although the sigmoidal nature of the NTCP
model produced somewhat flatter cost around the minima,
which implies that good therapeutic response is less sen-
sitive to perturbations and is therefore easier to achieve.
Alternative NTCP models also exist (see e.g., [54–57])
although most tend to be static (as opposed to dynamic, or
temporal) and empirically founded.
Dynamic models of toxicity have also been developed.
In [58] Krzyzanski et al. proposed a model of thrombo-
cytopenia following combined chemotherapy and radiation
treatment. Scenarios when the tumor model as well as the
toxicity model are both dynamic can be approached using
optimal control theory [59, 60]. The approach to selecting
and ranking combinations presented in this paper could
also be used in combination with other optimization
approaches such as those that design treatment protocols to
yield the most amount of information about the compounds
[61, 62].
Conclusions and perspectives
We have demonstrated how a model-based approach, using
TSE, can be used to compare and rank radiation and
radiosensitizer combinations. The analysis weighs efficacy
(tumor regression) against side-effects (toxicity) in order to
provide a fair comparison and ranking of the different
combinations.
While the chosen criteria for comparing combination
therapies are natural, they are not the only reasonable
choice. An alternative choice could be to compare the rate
of tumor regression for each combination at a specified
maximum tolerable exposure, i.e., exchanging the roles
that efficacy and toxicity play in the optimization problem.
Our analysis is focused on radiotherapy combined with
radiosensitizing treatment. A similar approach using TSE
and cost functions could also be considered for chemical
combinations. However, the underlying pharmacokinetic,
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pharmacodynamic, and toxicity modeling would have to
account for potential drug interactions.
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55. Kinclová I et al (2020) Model-based calculation of thyroid gland
normal tissue complication probability in head and neck cancer
patients after radiation therapy. Strahlenther Onkol
196(6):561–568
56. Stieb S et al (2021) NTCP modeling of late effects for head and
neck cancer: a systematic review. Int J Part Ther 8(1):95–107
57. Wals A et al (2006) Damage assessment in gastric cancer treat-
ment with adjuvant radiochemotherapy: calculation of the
NTCP’s from the differential HDV of the organs at risk. Clin
Transl Oncol 8(4):271–278
58. Krzyzanski W et al (2015) Pharmacodynamic model for
chemoradiotherapy-induced thrombocytopenia in mice. J Phar-
macokinet Pharmacodyn 42(6):709–720
59. Moore H (2016) How to mathematically optimize drug regimens
using optimal control. J Pharmacokinet Pharmacodyn
45(1):127–137
60. Bruni C et al (2015) Optimal weekly scheduling in fractionated
radiotherapy: effect of an upper bound on the dose fraction size.
J Math Biol 71(2):361–398
61. Lestini G et al (2016) Optimal design for informative protocols in
xenograft tumor growth inhibition experiments in mice. AAPS J
18(5):1233–1243
62. Floc’h N et al (2018) Optimizing the design of population-based
patient-derived tumor xenograft studies to better predict clinical
response. Dis Model Mech 11(11):dmm036160
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Journal of Pharmacokinetics and Pharmacodynamics
123
